14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for MBRX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.46 5.96 %
R2 5.36 4.10 %
R1 5.30 2.95 %
Current price: 5.15
Support S1 5.11 -0.760 %
S2 5.05 -1.91 %
S3 4.96 -3.76 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.70 10.77 %
R2 5.54 7.57 %
R1 5.25 1.94 %
Current price 5.15
Support S1 5.01 -2.72%
S2 4.68 -9.13%
S3 4.52 -12.17%

MBRX Predictions History

5 years ago
PumpTheseNumbers predicted that MBRX for 2019-04-26 is going $1.59 (11.97%)

5 years ago
James.Rowery.108979 predicted that MBRX for 2019-04-26 is going $0.498 (-65.89%)

Rank:

5 years ago
JS predicted that MBRX for 2019-04-24 is going $1.86 (6.90%)

5 years ago
NameNotImportant predicted that MBRX for 2019-04-24 is going $1.16 (-27.04%)

5 years ago
ss predicted that MBRX for 2019-04-22 is going $1.20 (8.11%)

Rank:

5 years ago
Profit.Prophet.108044 predicted that MBRX for 2019-04-22 is going $1.05 (-5.41%)

5 years ago
JS predicted that MBRX for 2019-04-22 is going $1.00 (-10.18%)

5 years ago
PumpTheseNumbers predicted that MBRX for 2019-04-22 is going $1.08 (-2.70%)

5 years ago
NameNotImportant predicted that MBRX for 2019-04-22 is going $1.01 (-9.01%)

Click to get the best stock tips daily for free!

About Moleculin Biotech Inc

Moleculin Biotech Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo... MBRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT